Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.

Pathogenic microorganisms encode proteins that antagonize specific aspects of innate or adaptive immunity. Just as the study of the HIV-1 accessory protein Vif led to the identification of cellular cytidine deaminases as host defense proteins, the study of HIV-1 Vpu recently led to the discovery of the interferon-induced transmembrane protein BST-2 (CD317; tetherin) as a novel component of the innate defense against enveloped viruses. BST-2 is an unusually structured protein that restricts the release of fully formed progeny virions from infected cells, presumably by a direct retention mechanism that is independent of any viral protein target. Its spectrum of activity includes at least four virus families: retroviruses, filoviruses, arenaviruses, and herpesviruses. Viral antagonists of BST-2 include HIV-1 Vpu, HIV-2 and SIV Env, SIV Nef, the Ebola envelope glycoprotein, and the K5 protein of KSHV. The mechanisms of antagonism are diverse and currently include viral cooption of cellular endosomal trafficking and protein degradation pathways, including those mediated by ubiquitination. Orthologs of human BST-2 are present in mammals. Primate BST-2 proteins are differentially sensitive to antagonism by lentiviral Vpu and Nef proteins, suggesting that BST-2 has subjected lentiviruses to evolutionary pressure and presents barriers to cross-species transmission. BST-2 functions not only as an effector of the interferon-induced antiviral response but also as a negative feedback regulator of interferon production by plasmacytoid dendritic cells. Future work will focus on the role and regulation of BST-2 during the innate response to viral infection, on the mechanisms of restriction and of antagonism by viral gene products, and on the role of BST-2 in primate lentiviral evolution. The augmentation of BST-2 activity and the inhibition of virally encoded antagonists, in particular Vpu, represent new approaches to the prevention and treatment of HIV-1 infection.

[1]  U. Schubert,et al.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains , 1996, Journal of virology.

[2]  Carlos F. Lopez,et al.  Molecular dynamics investigation of membrane-bound bundles of the channel-forming transmembrane domain of viral protein U from the human immunodeficiency virus HIV-1. , 2002, Biophysical journal.

[3]  D. Pillay,et al.  Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration , 2009, Proceedings of the National Academy of Sciences.

[4]  T. Sata,et al.  HIV-1 Accessory Protein Vpu Internalizes Cell-surface BST-2/Tetherin through Transmembrane Interactions Leading to Lysosomes* , 2009, The Journal of Biological Chemistry.

[5]  Takeshi Yoshida,et al.  Comparative study on the effect of human BST-2/Tetherin on HIV-1 release in cells of various species , 2009, Retrovirology.

[6]  A. Sakurai,et al.  Dimerization of Tetherin Is Not Essential for Its Antiviral Activity against Lassa and Marburg Viruses , 2009, PloS one.

[7]  G. Ruthel,et al.  In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Spearman,et al.  Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Paraskevis,et al.  Characterization of a Novel vpu-Harboring Simian Immunodeficiency Virus from a Dent's Mona Monkey (Cercopithecus mona denti) , 2005, Journal of Virology.

[10]  Martine Peeters,et al.  Hybrid Origin of SIV in Chimpanzees , 2003, Science.

[11]  G. Melikyan,et al.  HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes , 2009, Cell.

[12]  C. Castilletti,et al.  Effects of IFNα on late stages of HIV-1 replication cycle , 1998 .

[13]  Yunkai Yu,et al.  Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.

[14]  M. Salemi,et al.  Characterization of a Novel Simian Immunodeficiency Virus with a vpu Gene from Greater Spot-Nosed Monkeys (Cercopithecus nictitans) Provides New Insights into Simian/Human Immunodeficiency Virus Phylogeny , 2002, Journal of Virology.

[15]  T. Deerinck,et al.  Direct Restriction of Virus Release and Incorporation of the Interferon-Induced Protein BST-2 into HIV-1 Particles , 2010, PLoS pathogens.

[16]  Michael Emerman,et al.  HIV-1 accessory proteins--ensuring viral survival in a hostile environment. , 2008, Cell host & microbe.

[17]  R. Schreiber,et al.  Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation1 , 2006, The Journal of Immunology.

[18]  É. Cohen,et al.  Suppression of Tetherin-Restricting Activity upon Human Immunodeficiency Virus Type 1 Particle Release Correlates with Localization of Vpu in the trans-Golgi Network , 2009, Journal of Virology.

[19]  Ronald S Veazey,et al.  A macaque model of HIV-1 infection , 2009, Proceedings of the National Academy of Sciences.

[20]  A. O. Ajao,et al.  Characterization of a Novel Simian Immunodeficiency Virus (SIVmonNG1) Genome Sequence from a Mona Monkey (Cercopithecus mona) , 2003, Journal of Virology.

[21]  P. Bates,et al.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein , 2009, Proceedings of the National Academy of Sciences.

[22]  V. Korolchuk,et al.  Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif , 2007, Journal of Cell Science.

[23]  S. Westmoreland,et al.  Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2 , 2009, PLoS pathogens.

[24]  R. Benarous,et al.  Vpu Antagonizes BST-2–Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking , 2009, PLoS pathogens.

[25]  B. Strack,et al.  Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.

[26]  B. Klupp,et al.  Herpesvirus assembly: an update. , 2009, Virus research.

[27]  E. Marbán,et al.  Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. , 2004, Molecular cell.

[28]  P. Bieniasz,et al.  Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin , 2008, Journal of Virology.

[29]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[30]  J. Guatelli,et al.  HIV‐1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin‐coated, Gag‐containing endosomes , 2008, Cellular microbiology.

[31]  D. Thomas,et al.  A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. , 1998, Molecular cell.

[32]  M. Wainberg,et al.  The Transmembrane Domain of BST-2 Determines Its Sensitivity to Down-Modulation by Human Immunodeficiency Virus Type 1 Vpu , 2009, Journal of Virology.

[33]  Marc C. Johnson,et al.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.

[34]  Michael Emerman,et al.  An In Vitro Rapid-Turnover Assay for Human Immunodeficiency Virus Type 1 Replication Selects for Cell-to-Cell Spread of Virus , 2000, Journal of Virology.

[35]  F. Jensen,et al.  Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Yuko Hirota,et al.  HM1.24 Is Internalized from Lipid Rafts by Clathrin-mediated Endocytosis through Interaction with α-Adaptin* , 2009, The Journal of Biological Chemistry.

[37]  D. Pinson,et al.  Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques. , 2002, Virology.

[38]  Marc C. Johnson,et al.  Nef proteins from simian immunodeficiency viruses are tetherin antagonists. , 2009, Cell host & microbe.

[39]  T. Noda,et al.  Inhibition of Lassa and Marburg Virus Production by Tetherin , 2008, Journal of Virology.

[40]  J. Sodroski,et al.  Identification of a protein encoded by the vpu gene of HIV-1 , 1988, Nature.

[41]  H. Akari,et al.  Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. , 2003, Virology.

[42]  A. Ryo,et al.  BCA2/Rabring7 Promotes Tetherin-Dependent HIV-1 Restriction , 2009, PLoS pathogens.

[43]  S. Neil,et al.  Antagonism to and Intracellular Sequestration of Human Tetherin by the Human Immunodeficiency Virus Type 2 Envelope Glycoprotein , 2009, Journal of Virology.

[44]  K. Strebel,et al.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion , 2009, Proceedings of the National Academy of Sciences.

[45]  P. Bieniasz,et al.  Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants , 2009, PLoS pathogens.

[46]  W. Sundquist,et al.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. , 2007, Cell host & microbe.

[47]  W. Haseltine,et al.  Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. McCormack,et al.  Quantitative Membrane Proteomics Reveals New Cellular Targets of Viral Immune Modulators , 2006, PLoS pathogens.

[49]  J. Petriz,et al.  Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. , 2005, Cellular immunology.

[50]  A. Moses,et al.  Molecular Mechanism of BST2/Tetherin Downregulation by K5/MIR2 of Kaposi's Sarcoma-Associated Herpesvirus , 2009, Journal of Virology.

[51]  P. Cannon,et al.  Functional Domains within the Human Immunodeficiency Virus Type 2 Envelope Protein Required To Enhance Virus Production , 2005, Journal of Virology.

[52]  H. Kräusslich,et al.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. , 2009, Cell host & microbe.

[53]  Y. Kawaoka,et al.  Selection of H5N1 Influenza Virus PB2 during Replication in Humans , 2009, Journal of Virology.

[54]  T. Klimkait,et al.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release , 1990, Journal of virology.

[55]  George Banting,et al.  Bst‐2/HM1.24 Is a Raft‐Associated Apical Membrane Protein with an Unusual Topology , 2003, Traffic.

[56]  D. Pillay,et al.  Mutation of a Single Residue Renders Human Tetherin Resistant to HIV-1 Vpu-Mediated Depletion , 2009, PLoS pathogens.

[57]  P. Henklein,et al.  Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV‐1‐infected cells , 1996, FEBS letters.

[58]  M. Emerman,et al.  Simian Immunodeficiency Virus SIVagm from African Green Monkeys Does Not Antagonize Endogenous Levels of African Green Monkey Tetherin/BST-2 , 2009, Journal of Virology.

[59]  P. Bieniasz,et al.  HIV-1 Vpu Promotes Release and Prevents Endocytosis of Nascent Retrovirus Particles from the Plasma Membrane , 2006, PLoS pathogens.

[60]  Jonathan Casper,et al.  Combining local‐structure, fold‐recognition, and new fold methods for protein structure prediction , 2003, Proteins.

[61]  A. Moses,et al.  Vpu Directs the Degradation of the Human Immunodeficiency Virus Restriction Factor BST-2/Tetherin via a βTrCP-Dependent Mechanism , 2009, Journal of Virology.

[62]  K. Ikuta,et al.  Interferon-alpha treatment leads to accumulation of virus particles on the surface of cells persistently infected with the human immunodeficiency virus type 1. , 1990, Journal of acquired immune deficiency syndromes.

[63]  Marc C. Johnson,et al.  Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells , 2009, Cell.

[64]  M. Tsuchiya,et al.  Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. , 1999, Biochemical and biophysical research communications.

[65]  Aaron Derdowski,et al.  The Pericentriolar Recycling Endosome Plays a Key Role in Vpu‐mediated Enhancement of HIV‐1 Particle Release , 2006, Traffic.

[66]  J. Luban,et al.  HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation , 2009, PLoS pathogens.

[67]  T. Klimkait,et al.  A novel gene of HIV-1, vpu, and its 16-kilodalton product. , 1988, Science.

[68]  S. Opella,et al.  Three-dimensional structure of the transmembrane domain of Vpu from HIV-1 in aligned phospholipid bicelles. , 2006, Biophysical journal.

[69]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[70]  K. Früh,et al.  Viral Modulators of Cullin RING Ubiquitin Ligases: Culling the Host Defense , 2006, Science's STKE.

[71]  M. Farzan,et al.  A New World Primate Deficient in Tetherin-Mediated Restriction of Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.

[72]  Dzung H. Nguyen,et al.  Evidence for Budding of Human Immunodeficiency Virus Type 1 Selectively from Glycolipid-Enriched Membrane Lipid Rafts , 2000, Journal of Virology.

[73]  U. Schubert,et al.  The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? , 1996, Journal of virology.

[74]  K. Strebel,et al.  The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu , 2009, Retrovirology.

[75]  A. Adachi,et al.  Function of human immunodeficiency virus type 1 Vpu protein in various cell types. , 1995, The Journal of general virology.

[76]  M. Montal.  Vpu Matchmakers as a Therapeutic Strategy for HIV Infection , 2009, PLoS pathogens.